Boston-headquartered Tango Therapeutics (TNGX) stock surged on Monday, driven by encouraging results from a pancreatic cancer trial.
TNGX is a clinical-stage biotech firm focused on discovering and delivering next-gen precision cancer medicines, and the pancreatic cancer trial appears to have validated its therapeutic approach in a particularly difficult-to-treat cancer type.